Critics demand stop to 'Guinea pig' sepsis clinical trial

Critics demand stop to 'Guinea pig' sepsis clinical trial

(HealthDay)—A major non-profit advocacy group is asking that a large government trial comparing treatments for sepsis be shut down.

The trial, called Clovers, "places seriously ill patients at risk without the possibility of gaining information that can provide benefits either to the subjects or to future patients," according to an analysis of the trial by investigators at the U.S. National Institutes of Health Clinical Center in Bethesda, Md. And in a letter sent to the federal Office for Human Research Protection, Public Citizen compared the study to "an experiment that would be conducted on laboratory animals," The New York Times reported.

"The human subjects of the Clovers trial, as designed and currently conducted, are unwitting guinea pigs in a physiology experiment," Public Citizens' Michael Carome, M.D., and Sidney Wolfe, M.D., wrote in their letter. The Clovers trial began in March and is funded by the NIH. It is moving forward and hopes to enroll 2,320 patients from 44 hospitals nationwide.

The Clovers trial seeks to determine which one of two therapeutic options—limiting fluids and starting vasopressors, or adding and holding off on drug therapy—works best to curb .

More information: The New York Times Article
Clovers Clinical Trial

Copyright © 2018 HealthDay. All rights reserved.

Citation: Critics demand stop to 'Guinea pig' sepsis clinical trial (2018, September 26) retrieved 24 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Clinical trial fails to disclose risk of death, repeat heart attacks, advocacy group says


Feedback to editors